ATH 14.3% 0.3¢ alterity therapeutics limited

Longs - SP and Bashers with multiple userids, page-25

  1. 332 Posts.
    lightbulb Created with Sketch. 17
    This is a coherent explanation of ANAVEX 2-73 and the current trial... http://www.anavex.com/?post_type=news&p=1165

    "The first part is a scheduled Phase 1b/2a trial of approximately 40 patients who will receive either ANAVEX 2-73 or standard of care (donepezil) with ANAVEX 2-73. The study will explore dose and schedule as well as the efficacy of the combination. Patients in this study will have the option to rollover into a single open-label study in order to further accumulate safety, tolerability and efficacy data.
    The second part of the study is designed as a double-blind Phase 2 trial and will randomize AD patients to standard of care (donepezil) or standard of care (donepezil) with ANAVEX 2-73 with a primary outcome measure at 26 weeks efficacy based on standard cognitive measures. All patients from this second study will also have the option to rollover into the single open-label study in order to further accumulate safety, tolerability and efficacy data."

    And here's an article about the novel measurement technique being used (anybody else scared for Anavex?) http://alzheimersnewstoday.com/2014...th-neuronetrix-for-alzheimers-clinical-trial/

    I hope it goes well for Anavex (more accurately for AD sufferers), but it is clearly very early in what we know to be a long process.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
-0.001(14.3%)
Mkt cap ! $15.96M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $11.18K 3.279M

Buyers (Bids)

No. Vol. Price($)
38 52064257 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 126697935 22
View Market Depth
Last trade - 16.10pm 16/08/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.